Ozempic and Wegovy has been prescribed to Yorkshire patients hundreds of times in the past year - and it's not for weightloss ...

Oral semaglutide administered via the RaniPill® HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and ...

Novo Nordisk's CEO is not worried about blockbuster semaglutide drugs being added to Medicare drug pricing negotiations this ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

More prescriptions were handed out for semaglutide – a drug used to treat diabetes – in Buckinghamshire last year, figures ...

More prescriptions were handed out for semaglutide – a drug used to treat diabetes – in Hull last year, figures show.

The search for effective weight loss solutions has led to countless diet trends, fitness regimens, and medical interventions.

Finally, a few studies in mice have found that the medications can reduce the buildup of the protein tau in the brain, which is a key contributor to Alzheimer’s disease. Scaling back tau buildup could ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...